Skip to main content

Market Overview

BioCopy, Immatics Team Up For Characterization Of TCR-Peptide-HLA Interactions

Share:
BioCopy, Immatics Team Up For Characterization Of TCR-Peptide-HLA Interactions
  • Switzerland-based BioCopy AG has collaborated with Immatics N.V. (NASDAQ: IMTXto characterize T cell receptors (TCRs).  
  • T cell receptors and their interactions with peptide-HLA complexes (human leukocyte antigen) play a crucial role for the human immune system in recognition of tumors, among other things. 
  • BioCopy's technology enables high-throughput screening of T cell receptors for binding to a wide variety of peptide-HLA complexes, thus contributing a safety screening for novel TCR-based cancer cell therapies. 
  • This collaboration aims to enable the characterization of more than 5,000 different TCR-peptide-HLA interactions simultaneously to accelerate the development of T-cell-based cancer therapies by facilitating large pre-clinical safety screenings. 
  • Price Action: IMTX shares are down 0.34% at $11.75 on the last check Wednesday.
 

Related Articles (IMTX)

View Comments and Join the Discussion!

Posted-In: BriefsBiotech News Health Care Contracts Small Cap General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com